When a mother with RhD-negative blood is pregnant with a baby that has RhD-positive blood, there is a risk her immune system will create antibodies that go on to attack the red blood cells of her next RhD-positive baby. This is known as “Rhesus Disease”, which can have serious and potentially fatal outcomes for newborn babies.
Human-plasma-derived anti-RhD immunoglobulin (anti-D IgG) medicinal products are currently the only available treatment in Europe capable of preventing Rhesus disease in pregnant women. Today, the anti-D IgG products used in Europe are almost exclusively produced from US plasma donors.
The lack of self-sufficiency in anti-D plasma and anti-D IgG products in Europe is of public health concern, with patients being put at risk in the event of a sudden plasma supply shortage when no current alternatives exist on the European market.
While there is a need for self-sufficiency in the provision of anti-D treatment in Europe, the supply of anti-D plasma and production of plasma-derived anti-D IgG is limited and poses many challenges.
This series of three webinars raises awareness on the challenges in the collection of anti-D plasma, the production of plasma-derived anti-D IgG products and will explore potential solutions including the development and use of alternative and complimentary anti-D products.
This webinar series is of interest to all professionals working in the provision of anti-D treatment, blood establishments, manufacturers and clinicians involved in the collection of plasma, manufacture of plasma-derived anti-D IgG products and clinical use of anti-D IgG products, regulatory professionals and policy makers.
Register to watch the webinars
Download the presentations